Gallium Ga-68 Dotatate

The targeting chemistry is identical to lutetium Lu-177 dotatate — the same octreotate peptide, the same DOTA cage — but the cage holds gallium-68, a positron emitter with a 68-minute physical half-life. Positron annihilation produces paired 511 keV photons that PET detects with far better spatial resolution and sensitivity than the older indium-111 octreotide scan it replaced. Because uptake is proportional to receptor density, the scan is not merely anatomical: the intensity of uptake, usually expressed as an SUVmax or a Krenning score, is what determines whether a patient is a candidate for peptide receptor radionuclide therapy. Physiological uptake in spleen, kidneys, adrenals, pituitary and pancreatic uncinate process is normal and must not be read as disease.

Targets: Somatostatin receptor 2 (SSTR2), Somatostatin receptor 5 (SSTR5)

• · About 2 MBq/kg (0.054 mCi/kg) up to a maximum of roughly 200 MBq (5.4 mCi). Long-acting somatostatin analogues are usually held for around 3 to 4 weeks beforehand so they do not block the receptor and mask disease.

Work out your exact syringe units →

• very commonNo clinically meaningful pharmacologic effects— The injected peptide mass is in the microgram range — far below any dose that would produce somatostatin effects.
• very commonDiagnostic radiation exposure— Roughly comparable to a diagnostic CT; a genuine but small long-term consideration in young patients scanned repeatedly.
• uncommonInjection-site reaction— Transient stinging or flushing at the cannula.
• rareNausea or dizziness— Brief and self-limiting.

• Pregnancy — the risk is small at diagnostic activity but scans are deferred or justified case by case.
• Breastfeeding should be interrupted for around 12 hours after injection.

• conflictLong-acting octreotide or lanreotide — Receptor occupancy by cold analogue reduces tracer uptake and can produce false negatives; depots are usually held for 3 to 4 weeks.
• synergylu-177-dotatate — This scan is the gatekeeper for PRRT — no somatostatin receptor expression, no Lutathera.

• · No laboratory monitoring is required for the tracer itself.
• · Report the Krenning score or SUVmax, since receptor density determines PRRT eligibility.
• · Read against the physiological uptake pattern — spleen, kidneys, adrenals, pituitary and pancreatic uncinate process light up normally.

FDA approved (Netspot, 2016) and widely available in the EU. Restricted to licensed nuclear medicine departments.

• FDA prescribing information for Netspot (kit for gallium Ga-68 dotatate injection) (label)
• SNMMI and EANM practice guideline for somatostatin receptor PET/CT in neuroendocrine tumours (guideline)

The chemistry is the therapeutic drug with a different metal in the cage, so everything in the lutetium record about SSTR2 agonism and internalisation applies here too. What is worth understanding separately is why the image means what it means. Gallium-68 is a positron emitter; the emitted positron travels a short distance, annihilates with an electron and produces two 511 keV photons at 180 degrees, which is what a PET ring detects in coincidence. Because uptake is receptor-density-dependent and internalisation keeps accumulating signal across the uptake period, the intensity of a lesion is a semi-quantitative measure of how many SSTR2 molecules are there. That is the reason this scan is not merely anatomical: the Krenning score, which grades lesion uptake against liver and spleen, and the SUVmax are the actual gatekeepers for peptide receptor radionuclide therapy. A Krenning score of 3 or 4 — uptake at or above liver, or at or above spleen — is what most centres require before treating. The most important interpretive fact is that physiological uptake is intense and normal in spleen, kidneys, adrenals, pituitary and the pancreatic uncinate process, and that uncinate uptake in particular has sent people to unnecessary surgery. The second is that dedifferentiated, higher-grade tumour loses somatostatin receptor and gains glucose avidity, so a patient with mismatched lesions — some dotatate-positive, some FDG-positive and dotatate-negative — has a worse prognosis and is a poor PRRT candidate no matter how good the dotatate scan looks in isolation.

Almost every problem with this scan is interpretive rather than toxic. Physiological uncinate process uptake gets called a pancreatic primary. Splenules and accessory spleens after splenectomy get called peritoneal metastases. Inflammatory and granulomatous tissue expresses somatostatin receptors and lights up. Vertebral haemangiomas take up tracer and get called bone metastases. Recent surgery or radiation leaves receptor-positive inflammation for months. On the other side, a false negative in a patient on a depot analogue can cost someone access to the single most effective therapy for their disease. And the structural failure mode is logistical rather than biological — the 68-minute half-life means the dose is made on site with a hard clock, and a late patient or a failed quality control run wastes the whole preparation.

• Somatostatin receptor 2 (SSTR2) — Sub-nanomolar to low-nanomolar; the gallium-loaded form is reported to bind SSTR2 slightly more tightly than the lutetium-loaded form, which is a real and slightly awkward detail when the scan is used to predict therapy uptake

  Agonist binding and internalisation, giving a signal proportional to receptor density. This is what the Krenning score is grading.

• Somatostatin receptor 5 (SSTR5) — Much weaker than SSTR2

  Negligible contribution to image contrast.

• Physiological SSTR2 in spleen, kidney, adrenal, pituitary and pancreatic uncinate process — Normal tissue expression

  Intense normal uptake that must be recognised rather than reported. Uncinate process uptake is the classic false positive.

Injection, then a 40 to 90 minute uptake period, then roughly 20 to 30 minutes on the scanner. The whole visit is about two hours. There is no pharmacological onset to speak of because the injected peptide mass is micrograms, far below anything that would produce somatostatin effects. The result is usually available within a day or two; the number that changes management is the Krenning score, not the report's adjectives.

The one interaction that matters is with cold somatostatin analogues. Long-acting octreotide or lanreotide occupies the receptor and can blunt or abolish tracer uptake, producing a false negative in a patient who would in fact have benefited from therapy, so depots are usually held around 3 to 4 weeks and short-acting octreotide 24 hours. There is an unresolved argument in the field about whether this matters as much as everyone assumes — some data suggest the depot mainly reduces spleen and liver background and can actually improve tumour-to-background ratio — but the conservative practice remains to hold. The genuinely useful pairing is with FDG PET. A dual-tracer approach, sometimes scored as the NETPET grade, identifies the mismatch pattern where some lesions are receptor-positive and others are glucose-avid and receptor-negative, and that mismatch predicts a much worse outcome from PRRT than the dotatate scan alone would suggest. If someone is being worked up for PRRT and only one scan is being done, that is a gap.

Against indium-111 pentetreotide scintigraphy, the OctreoScan it replaced, this is not a small improvement — the spatial resolution, sensitivity and lesion detection are all substantially better, and it is a same-day study rather than a two-day one. Against copper Cu-64 dotatate, marketed as Detectnet, the targeting peptide is identical but the 12.7-hour isotope removes the on-site generator requirement and lets doses be shipped, which is a real access advantage; image quality is broadly comparable. Against FDG PET, these are complementary rather than competing — dotatate finds well-differentiated receptor-expressing disease, FDG finds the dedifferentiated clone, and the patients you most want to identify are the ones who show both. Against the therapeutic lutetium version, the only chemical difference is the metal, and the scan's whole purpose is to tell you whether that therapy will land.

Not characterised. This is a facility-billed imaging procedure with technical and professional components, and the charge varies by centre, payer and whether it is bundled with a CT. It is also not a monthly cost — it is a per-scan event, typically once at diagnosis and then every 6 to 12 months in surveillance.

• ?No volume of distribution, clearance or protein binding is published in the label, so those are left null rather than estimated from the therapeutic analogue.
• ?The tmax of 0.08 hours is an approximation representing the end of a bolus injection; it is not a reported parameter and blood concentration is not the relevant kinetic here anyway.
• ?The claim that gallium-loaded DOTATATE binds SSTR2 somewhat more tightly than the lutetium-loaded form is reported in the radiochemistry literature but I did not resolve a primary source in this pass. It matters because the scan is used to predict therapy uptake.
• ?Whether long-acting somatostatin analogues genuinely need to be held before scanning is contested. The conservative 3 to 4 week hold is standard practice rather than settled evidence.
• ?The Krenning score thresholds used for PRRT eligibility vary between centres and are not standardised in a way that would let a single number be quoted.
• ?The comparative sensitivity figures against OctreoScan come from the general literature rather than a study resolved here.

• NETSPOT (kit for the preparation of gallium Ga 68 dotatate injection) — US prescribing information Advanced Accelerator Applications, FDA prescribing information

  Source of the 12 percent urinary excretion at four hours, the 3.15 mSv effective dose at 150 MBq, and the list of physiological SSTR2-expressing organs that light up normally.

• Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors Strosberg J, El-Haddad G, Wolin E, et al., New England Journal of Medicine, 2017 · PMID 28076709

  Included here because this scan exists mainly to select patients for that trial's therapy. The eligibility criteria are the reason the Krenning score matters.